Navigation Links
Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today
Date:5/3/2011

o carefully read these documents before making any decision with respect to the cash tender offer.  These documents are available at no charge on the SEC's website at www.sec.gov.  In addition, a copy of the offer to purchase, letter of transmittal and certain related tender offer documents may be obtained free of charge by directing a request to Quest Diagnostics at 973-520-2900.  A copy of the tender offer statement and Celera's solicitation/recommendation statement on Schedule 14D-9 are available to all stockholders of Celera free of charge at www.celera.com.

As stated, the depositary for the tender offer is Computershare Trust Company, N.A.  The information agent for the tender offer is D.F. King & Co., Inc.  The dealer manager for the tender offer is Morgan Stanley & Co. Incorporated.

Contacts:
Kathleen Valentine (Investors):  973-520-2900
Gary Samuels (Media): 973-520-2800


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Patient Advocates File FOIA Request to FDA on Avastin
2. Shareholders to Challenge Johnson & Johnsons Support for Left-Wing Policy Agenda: CEO William C. Weldon to Be Questioned on Firms Failure to Disclose Financial Information on Firms ObamaCare Lobbying It Pledged to Release Last Year
3. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
4. PLC Systems Chief Financial Officer to Leave Company to Become CEO of Clinquest
5. Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants
6. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
7. NCPA Responds to Consumer Groups Request for CVS Caremark Divestiture
8. Quest Diagnostics to Release First Quarter 2011 Financial Results
9. Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards
10. MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras
11. FDA to Address Industry Questions About Biosimilar Regulations at the Pharmas IQ Immunogenicity Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH ) ... marketer of orthopedic implants in China, today announced that the ... August 16, 2011, before the market opens. Kanghui ... August 16, 2011 to discuss second quarter results and answer ...
... ATLANTA, July 28, 2011 Data presented this week at ... many people have low vitamin D levels and that testing ... to published data from the Third National Health and Nutrition ... only 23 percent of Americans have vitamin D levels over ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 2Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 3
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... Georgia (PRWEB) July 30, 2014 The ... and Technology Alliance of TAG (B&TA), today issued its ... TAG Excalibur Awards. , Interested companies have until August ... after which, Semi-Finalists will be selected by the Excalibur ... required to meet with the judges for interviewing process. ...
(Date:7/30/2014)... 30, 2014 As the controversy surrounding ... gynecological surgeries continues to grow, Bernstein Liebhard LLP notes ... calling for a ban on uterine morcellation. According to ... diagnosed with leiomyosarcoma following a hysterectomy that involved the ... her diagnosis, the aggressive cancer had progressed to Stage ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 The ... nutrition school, is pleased to announce that Arianna Huffington has ... the curriculum of the Health Coach Training Program . ... The Huffington Post, a world-renowned news and blogging site that ... is the author of fourteen books and was included on ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The report ... Others), by Application (Healthcare, Food, Water Treatment, Pulp & ... & ROW) - Global Trends & Forecasts to 2018". ... size of 229.54 kilotons by 2019, signifying a robust ... study. , Browse 83 market data tables and 33 ...
Breaking Medicine News(10 mins):Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4
... was true for males tying the knot with younger females, study ... men seven to nine years their junior could be upping their ... with a significantly younger guy raises a woman,s risk of death ... 12 issue of Demography . , Not that marrying much ...
... years ago, scientists at Beth Israel Deaconess Medical Center ... the Akt molecular pathway, a popular target for cancer ... Akt1 was actively preventing cancer cells from ... was actually promoting breast cancer cell migration. And, indeed, ...
... 22q11 deletion syndrome (also known as DiGeorge syndrome) ... having an estimated incidence of at least one ... of severity but a multisystem impact, with symptoms ... endocrine abnormalities, cleft palate, gastrointestinal problems, and neuropsychiatric ...
... National ... was recently awarded certification from the Women’s Business Enterprise National Council (WBENC). ... San Diego, CA ... provider of water conservation and water management services , was ...
... ... extension option with Novation the leading health care supply contracting company for more than 25,000 ... and nearly 15,000 members of Provista, LLC. , ... Santa Clara (Vocus) May 14, 2010 -- Lumenis Ltd., a global leader ...
... out of ten patients who discontinued their overactive bladder (OAB) ... or they couldn,t tolerate it, according to research in the ... US researchers also discovered that smokers, men with enlarged prostates ... to stop taking prescription drugs for bladder problems. The ...
Cached Medicine News:Health News:Women Who Marry Younger Men May Die Earlier 2Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:Without this protein, embryonic development halts 2Health News:National Water Services, Inc. Receives WBE Certification 2Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 2Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 3Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 4Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 2Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: